EA202090579A1 - PD-1-BINDING MOLECULES AND METHODS OF THEIR APPLICATION - Google Patents

PD-1-BINDING MOLECULES AND METHODS OF THEIR APPLICATION

Info

Publication number
EA202090579A1
EA202090579A1 EA202090579A EA202090579A EA202090579A1 EA 202090579 A1 EA202090579 A1 EA 202090579A1 EA 202090579 A EA202090579 A EA 202090579A EA 202090579 A EA202090579 A EA 202090579A EA 202090579 A1 EA202090579 A1 EA 202090579A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mat
binding
methods
antibodies
molecules
Prior art date
Application number
EA202090579A
Other languages
Russian (ru)
Inventor
Калпана Шах
Дуглас Х. Смит
Росс Ла Мотте-Мос
Лесли С. Джонсон
Пол А. Мур
Эцио Бонвини
Скотт Кёниг
Original Assignee
Макродженикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Макродженикс, Инк. filed Critical Макродженикс, Инк.
Publication of EA202090579A1 publication Critical patent/EA202090579A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к отобранным анти-PD-1 антителам, способным связываться как с PD-1 яванских макак, так и с PD-1 человека: MAT к PD-1, MAT 2 к PD-1, MAT 3 к PD-1, MAT 4 к PD-1, MAT 5 к PD-1, MAT 6 к PD-1, MAT 7 к PD-1, MAT 8 к PD-1, MAT 9 к PD-1, MAT 10 к PD-1, MAT 11 к PD-1, MAT 12 к PD-1, MAT 13 к PD-1, MAT 14 к PD-1 или MAT 15 к PD-1, а также гуманизированным и химерным вариантам указанных антител. Также изобретение относится к PD-1-связывающим молекулам, которые содержат PD-1-связывающие фрагменты указанных анти-PD-l антител, иммуноконъюгатам и биспецифическим молекулам, включая диатела, BiTE, биспецифические антитела и т.д., которые содержат (i) такие PD-1-связывающие фрагменты и (ii) домен, способный связываться с эпитопом молекулы, участвующей в регуляции контрольной точки иммунного ответа, присутствующей на поверхности иммунных клеток. Настоящее изобретение также относится к способам применения молекул, которые связываются с PD-1, для стимуляции иммунных ответов, а также способы детектирования PD-1.The present invention relates to selected anti-PD-1 antibodies capable of binding to both cynomolgus PD-1 and human PD-1: MAT to PD-1, MAT 2 to PD-1, MAT 3 to PD-1, MAT 4 to PD-1, MAT 5 to PD-1, MAT 6 to PD-1, MAT 7 to PD-1, MAT 8 to PD-1, MAT 9 to PD-1, MAT 10 to PD-1, MAT 11 to PD-1, MAT 12 to PD-1, MAT 13 to PD-1, MAT 14 to PD-1 or MAT 15 to PD-1, as well as humanized and chimeric variants of these antibodies. The invention also relates to PD-1 binding molecules that contain PD-1 binding fragments of said anti-PD-1 antibodies, immunoconjugates and bispecific molecules, including diabodies, BiTE, bispecific antibodies, etc., which contain (i) such PD-1 binding fragments; and (ii) a domain capable of binding to an epitope of a molecule involved in the regulation of an immune checkpoint present on the surface of immune cells. The present invention also relates to methods of using molecules that bind to PD-1 to stimulate immune responses, as well as methods of detecting PD-1.

EA202090579A 2016-04-15 2016-07-28 PD-1-BINDING MOLECULES AND METHODS OF THEIR APPLICATION EA202090579A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662322974P 2016-04-15 2016-04-15

Publications (1)

Publication Number Publication Date
EA202090579A1 true EA202090579A1 (en) 2020-09-30

Family

ID=72616022

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090579A EA202090579A1 (en) 2016-04-15 2016-07-28 PD-1-BINDING MOLECULES AND METHODS OF THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202090579A1 (en)

Similar Documents

Publication Publication Date Title
EA201890296A1 (en) PD-1-binding molecules and methods of their application
EA201792657A1 (en) Binding LAG-3 MOLECULES AND METHODS OF THEIR APPLICATION
CY1124771T1 (en) ANTI-SORTILINE ANTIBODIES AND METHODS OF USING THEM
PH12018501220A1 (en) Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
EA202092417A1 (en) CHIMERIC RECEPTORS TO DLL3 AND METHODS OF THEIR APPLICATION
MX2020004410A (en) Antibody compositions for tumor treatment.
EA201690167A1 (en) HUMANIZED OR CHEMICAL ANTIBODIES TO CD3
EA202190183A1 (en) ANTIBODIES TO SIGLEC-5 AND METHODS OF THEIR APPLICATION
EA202092595A1 (en) ANTIBODIES TO SIGLEC-7 AND METHODS OF THEIR APPLICATION
AR120117A2 (en) PD-1 BINDING MOLECULES AND METHODS OF USE THEREOF
EA202090579A1 (en) PD-1-BINDING MOLECULES AND METHODS OF THEIR APPLICATION
MY188871A (en) Pd-1-binding molecules and methods of use thereof
EA202090303A3 (en) ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS